While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Shares in biopharmaceutical group Gilead Sciences ($GILD) dropped 1% today after pharmacy firm CVS Health ($CVS) gave the thumbs down to its new ...

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. The regulator ordered the company to ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.

In the latest trading session, Gilead Sciences (GILD) closed at $105.93, marking a -1.18% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%.

GILD stock fell 21.3% from its high on December 29, 2021, to March 10, 2022, while the S&P 500 experienced a larger peak-to-trough decline of 25.4%. The stock fully recovered to its pre-crisis ...

Gilead reported revenues of $6.67 billion in the last reported quarter, representing a year-over-year change of -0.3%. EPS of $1.81 for the same period compares with -$1.32 a year ago.